73833-13-3

Basic information

• Product Name: Benzoic acid, 2-(chlorocarbonyl)-3-nitro-, methyl ester
• CAS NO: 73833-13-3
• Molecular Formula: C9H6ClNO5
• Molecular Weight: 243.603
• Mol File: 73833-13-3.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 2-(chlorocarbonyl)-3-nitro-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 2-(chlorocarbonyl)-3-nitro-, methyl ester(73833-13-3)
• EPA Substance Registry System: Benzoic acid, 2-(chlorocarbonyl)-3-nitro-, methyl ester(73833-13-3)

Safety Data

• Hazardous Substances Data: 73833-13-3(Hazardous Substances Data)

Upstream product

• 13365-26-9 dimethyl 3-nitrophthalate 
• 603-11-2 3-nitrophthalic acid 
• 21606-04-2 methyl 2-carboxy-3-nitrobenzoate 

Downstream Products

• 57113-90-3 methyl 2-(N-tert-butoxycarbonylamino)-3-nitrobenzoate 
• 145040-37-5 candesartan cilexetil 
• 139481-72-4 2-Ethoxy-1-[[2'-(N-triphenylmethyltetrazol-5-yl)-biphenyl-4-yl]methyl]benzimidazole-7-carboxylic acid 
• 150058-27-8 2-ethoxy-1H-benzimidazole-7-carboxylic acid methyl ester 
• 57113-91-4 methyl 3-nitroanthranilate 
• 107582-20-7 2,3-diaminobenzoic acid methyl ester 
• 139481-59-7 candesartan 
• 139482-06-7 3-[2'-(1H-Tetrazol-5-yl)-biphenyl-4-ylmethyl]-2-(2,2,2-trifluoro-ethoxy)-3H-benzoimidazole-4-carboxylic acid methyl ester 
• 139481-97-3 2-Morpholin-4-yl-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid methyl ester 
• 139481-98-4 2-Piperidin-1-yl-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid methyl ester 
• 139481-96-2 2-Butylamino-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid methyl ester 
• 150058-11-0 4'-{[tert-Butoxycarbonyl-(2-methoxycarbonyl-6-nitro-phenyl)-amino]-methyl}-biphenyl-2-carboxylic acid methyl ester 
• 136284-88-3 2-Ethylsulfanylmethyl-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid ethyl ester 
• 139481-71-3 2-Propylamino-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid ethyl ester 

Relevant articles and documents

Synthesis Method for Candesartan Cilexetil Intermediate

A synthesis method for a candesartan cilexetil intermediate represented by formula (II) is provided. The method includes (1) dissolving a compound represented by formula (IV) to an aprotic solvent to obtain a first mixed solution, and dissolving a phase transfer catalyst and an azidation reagent to water to obtain a second mixed solution; (2) dropping the first mixed solution to the second mixed solution for azidation reaction, and after the reaction is ended, standing and layering same to obtain an organic phase containing a compound represented by formula (V); (3) dropping the obtained organic phase containing the compound represented by formula (V) to tertiary butyl alcohol for rearrangement reaction, and after the reaction is ended, concentrating same to obtain a solid or oily material, then adding a crystallizing solvent to the obtained solid or oily material for recrystallization, and separating same to obtain a crystal.

PROCESS FOR PREPARATION OF CANDESART AN CILEXETIL SUBSTANTIALLY FREE OF DES-CANDESARTAN CILEXETIL IMPURITY

The present invention provides a process for preparation of candeartan cilexetil substantially free of 2,3-dihydro-2-oxo-3-[[2'-(2H-tetrazol-5-yl)[l,l-biphenyl]-4- yl]methyl]-l-[[(cyclohexyloxy)carbonyl]oxy]ethylester-lH-benzimidazole-7- carboxylate (des-candesartan cilexetil) impurity.

METHOD FOR PRODUCTION OF CANDESARTAN

The invention relates to novel methods for the production of Candesartan, or a protected form of Candesartan, a Candesartan salt or ester, compounds of application in said method, methods for production thereof, use thereof in said method, a novel polymorph of Candesartan cilexetil, a method for production and use thereof for production of a medicament.